BR112023018932A2 - Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular - Google Patents
Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocularInfo
- Publication number
- BR112023018932A2 BR112023018932A2 BR112023018932A BR112023018932A BR112023018932A2 BR 112023018932 A2 BR112023018932 A2 BR 112023018932A2 BR 112023018932 A BR112023018932 A BR 112023018932A BR 112023018932 A BR112023018932 A BR 112023018932A BR 112023018932 A2 BR112023018932 A2 BR 112023018932A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- ocular
- pharmaceutically acceptable
- ocular administration
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21166691 | 2021-04-01 | ||
| PCT/EP2022/058523 WO2022207773A1 (en) | 2021-04-01 | 2022-03-31 | Laquinimod formulation for ocular use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018932A2 true BR112023018932A2 (pt) | 2023-10-10 |
Family
ID=75362492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018932A BR112023018932A2 (pt) | 2021-04-01 | 2022-03-31 | Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240180819A1 (https=) |
| EP (2) | EP4461364B1 (https=) |
| JP (1) | JP2024516929A (https=) |
| KR (1) | KR20230165260A (https=) |
| CN (1) | CN117120035A (https=) |
| AU (1) | AU2022248724A1 (https=) |
| BR (1) | BR112023018932A2 (https=) |
| CA (1) | CA3212851A1 (https=) |
| ES (1) | ES3014261T3 (https=) |
| IL (1) | IL305997A (https=) |
| MX (1) | MX2023010971A (https=) |
| PL (1) | PL4312986T3 (https=) |
| WO (1) | WO2022207773A1 (https=) |
| ZA (1) | ZA202309969B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL320428A (en) | 2022-11-04 | 2025-06-01 | Qlaris Bio Inc | Topical ophthalmic administration of cromolyns |
| CN118892446A (zh) * | 2023-04-27 | 2024-11-05 | 维眸生物科技(浙江)有限公司 | 一种含vvn001的眼科组合物 |
| CN119523881A (zh) * | 2024-04-28 | 2025-02-28 | 中国人民解放军海军军医大学第二附属医院 | 一种s100a9抑制剂凝胶剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US20110052678A1 (en) * | 2010-11-05 | 2011-03-03 | Shantha Totada R | Method for treating age related macular degeneration |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| EP3068395A4 (en) * | 2013-11-15 | 2017-07-12 | Teva Pharmaceutical Industries Ltd. | Treatment of glaucoma using laquinimod |
| US9694003B2 (en) * | 2015-10-15 | 2017-07-04 | Bridge Pharma, Inc. | Formulations and methods for treating high intraocular pressure |
| IL289109B2 (en) * | 2019-06-19 | 2025-10-01 | Tarsus Pharmaceuticals Inc | Isoxazoline formulations against parasites and methods for treating blepharitis |
| KR20220118419A (ko) | 2019-12-19 | 2022-08-25 | 액티브 바이오테크 에이비 | 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물 |
-
2022
- 2022-03-31 PL PL22718720.0T patent/PL4312986T3/pl unknown
- 2022-03-31 US US18/284,284 patent/US20240180819A1/en active Pending
- 2022-03-31 KR KR1020237035464A patent/KR20230165260A/ko active Pending
- 2022-03-31 CA CA3212851A patent/CA3212851A1/en active Pending
- 2022-03-31 ES ES22718720T patent/ES3014261T3/es active Active
- 2022-03-31 CN CN202280022389.2A patent/CN117120035A/zh active Pending
- 2022-03-31 JP JP2023557096A patent/JP2024516929A/ja active Pending
- 2022-03-31 BR BR112023018932A patent/BR112023018932A2/pt unknown
- 2022-03-31 IL IL305997A patent/IL305997A/en unknown
- 2022-03-31 MX MX2023010971A patent/MX2023010971A/es unknown
- 2022-03-31 AU AU2022248724A patent/AU2022248724A1/en active Pending
- 2022-03-31 EP EP24203145.8A patent/EP4461364B1/en active Active
- 2022-03-31 EP EP22718720.0A patent/EP4312986B1/en active Active
- 2022-03-31 WO PCT/EP2022/058523 patent/WO2022207773A1/en not_active Ceased
-
2023
- 2023-10-25 ZA ZA2023/09969A patent/ZA202309969B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022248724A1 (en) | 2023-11-02 |
| MX2023010971A (es) | 2023-09-27 |
| KR20230165260A (ko) | 2023-12-05 |
| JP2024516929A (ja) | 2024-04-18 |
| US20240180819A1 (en) | 2024-06-06 |
| PL4312986T3 (pl) | 2025-02-17 |
| CA3212851A1 (en) | 2022-10-06 |
| EP4312986B1 (en) | 2024-10-23 |
| EP4461364A3 (en) | 2024-11-27 |
| CN117120035A (zh) | 2023-11-24 |
| ZA202309969B (en) | 2025-03-26 |
| EP4312986C0 (en) | 2024-10-23 |
| EP4461364A2 (en) | 2024-11-13 |
| EP4461364B1 (en) | 2026-04-22 |
| EP4312986A1 (en) | 2024-02-07 |
| WO2022207773A1 (en) | 2022-10-06 |
| ES3014261T3 (en) | 2025-04-21 |
| IL305997A (en) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023018932A2 (pt) | Formulação para administração ocular, recipiente de dosagem, uso de uma formulação, e, método para o tratamento de um transtorno ocular | |
| CO2026004076A2 (es) | Compuestos macrocíclicos, método de preparación de estos y uso de estos | |
| BRPI0707235B1 (pt) | formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual | |
| MX2017014804A (es) | Composiciones farmaceuticas topicas. | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| MX2024000828A (es) | Formulaciones de parasiticida de isoxazolina y metodos para el tratamiento de la blefaritis. | |
| AU2020213351B2 (en) | Methods of treating ocular conditions | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112021025701A2 (pt) | Formulações e métodos de parasiticida de isoxazolina para tratar blefarite | |
| BR0311414A (pt) | Agente terapêutico para uma bexiga hiperativa | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| KR20190024593A (ko) | 수면장애 예방 또는 치료용 조성물 | |
| WO2018031216A1 (en) | Treatment of disorders of sexual arousal with local application of agents that increase membrane excitability | |
| PH12019500597B1 (en) | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| MX2021007161A (es) | Agente que contiene acido ursodesoxicolico para tratar o prevenir la presbicia. | |
| JOP20250311A1 (ar) | مثبطات tyk2 وتركيبات وطرق لها | |
| BR112022024461A2 (pt) | Composição oftálmica tópica e método para o tratamento de um distúrbio oftálmico | |
| BR112022017856A2 (pt) | Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo | |
| JP7191022B2 (ja) | アルカフタジン又はその塩を含有する水性医薬組成物 | |
| ES2659458T3 (es) | Compuestos de naftaleno para tratar el prurito | |
| BR112021000183A8 (pt) | Preparação medicinal para uso externo | |
| JP6996775B2 (ja) | 個体の毛髪の成長を促進する、毛髪の抜けを予防する、または個体の毛包幹細胞の生成を促進する薬物の調製における組成物の用途 | |
| MX2022006803A (es) | Formulaciones oftalmicas para el tratamiento de la presbicia. |